Find the writing. Follow the thinking. Write back.
iFeed is a thinking practice in continuation. The substrate is on record — almost a decade of public writing across regulated science, a working bioanalytical foundation, and the methodology documented openly. The way to engage is the same way the writing emerged: read, think, write back.
The inbox, live. Read · think · write back.
Six recent threads · one is being written right nowThis is what engaging with iFeed actually looks like — an open inbox. Six recent threads, each from a real surface of the regulated-life-sciences world: a QA lead, a regulatory-affairs head, a validation engineer, a governance officer, an academic, a CRO operations lead. The first thread is live — being written back this moment. The loop never closes; the response becomes the next thing read.
Where the thinking surfaces.
Channels · with cadenceDaily-cadence thinking.
Where Sunita has been writing in essay-form since 2021. Regulatory thinking, book reflections, leadership essays, and now the iFeed long-form practice. The primary distribution channel.
The company page.
iFeed's company page on LinkedIn. Where the practice surfaces under the iFeed brand specifically — manifesto pieces, methodology references, regulator-watch synthesis.
Long-form weekly.
Long-form writing lives at iFeed.com/notes. Weekly cadence. Each piece anchors at iFeed and cross-posts to LinkedIn Articles. Read here, write back on LinkedIn.
Talking-head explainers.
8–10 minute pieces on the immunity model, the methodology, regulator-watch commentary — planned. Format will auto-embed into the relevant iFeed.com articles when the channel opens. Activation is subject to interest and feasibility; we will not announce a launch date until the substrate is ready to defend it.
Practitioner conversations.
Interview-format conversations with practitioners working at the intersection of regulated life sciences and AI-native execution — in design. Guest pipeline being scoped; format and cadence will be confirmed at launch.
Cohort learning.
Four cohort tracks under construction — EU AI Act readiness, validation of non-deterministic systems, GMP Annex 22, and ICH M10 bioanalytical method validation. Curriculum, faculty, and tuition posture are documented; pilot cohort activation is subject to interest and feasibility, and the open-intake cohort opens after the pilot closes successfully.
The cadence.
What you can expectOne long-form · three short-form.
Monday long-form lands at iFeed.com/notes and cross-posts to LinkedIn Articles. Three short-form thinking-out-loud posts during the week on Sunita's LinkedIn.
Synthesis piece · regulator watch.
Cumulative reflection of the month's notes. Regulator watch synthesis (FDA · EMA · MHRA · HPRA · ICH · WHO PQ). Updated bibliography in the library.
Domain deep-dive.
One deep-dive per operational domain — bioanalytical, bioequivalence, clinical trials — rotating quarterly. Reading-list refresh in the library.
What's worth writing back about.
Engagement framingWrite back if you are actually working on this.
- You are classifying AI deployments against the EU AI Act high-risk taxonomy and the worked examples are missing
- You are validating non-deterministic systems and the GAMP 5 framework needs reinterpretation
- You are preparing for GMP Annex 22 finalisation in H2 2026 and need to know what the inspection-readiness gap looks like
- You are running ICH M10 bioanalytical methods across multiple jurisdictions and need the convergence/divergence map
- You are operating an AI/ML medical device with a PCCP question and need the FDA-cleared template
- You are building an AI-native pharma startup and need quality systems architected from day one rather than retrofitted
- You are an AI engineer moving into the regulated industries and need the substrate to be legible